ABSTRACT
Objective To investigate the refracture and risk factors after percutaneous vertebroplasty (PVP) in the patients with hormone induced osteoporotic thoracolumbar vertebral fracture.Methods A total of 646 patients with osteoporotic thoracolumbar vertebral fractures in 425 Central Hospital of PLA from April 2010 to July 2015 were selected and divided into the primary osteoporotic thoracolumbar vertebral fractures(n=542) and hormone-induced osteoporotic thoracolumbar vertebral fractures(n=104) according to the fracture types.The incidence rate of refracture was compared between the two types of patients.The patients with hormone induced osteoporotic thoracolumbar fractures were divided into the fracture group and non-fracture group according to the refracture occurrence situation.The clinical data of the two groups were performed the univariate and multivariate Logistic regression analysis.Results There were 542 cases of primary osteoporosis,102 cases had refracture with the incidence rate of 18.82％,104 cases had hormone induced osteoporosis and 53 cases had refracture with the incidence rate of 50.96％.BMI,bone mineral density,bone cement leakage,preoperative vertebral fissure change and proportion of unreceiving anti-osteoporosis treatment had statistical difference between the fracture group and non-fracture group (P＜0.05).Bone mineral density,bone cement leakage,preoperative vertebral fissure change and no anti-osteoporosis treatment were the independent risk factors for refracture after PVP operation in the patients with steroid-induced thoracolumbar vertebral fracture (P＜0.05).Conclusion The patients with hormone induced osteoporotic thoracolumbar vertebral fracture have higher risk of refracture.Bone mineral density,bone cement leakage,preoperative vertebral fissure change,whether accepting anti-osteoporosis treatment are the major risk factors of refracture.
ABSTRACT
Objective To investigate the refracture and risk factors after percutaneous vertebroplasty (PVP) in the patients with hormone induced osteoporotic thoracolumbar vertebral fracture.Methods A total of 646 patients with osteoporotic thoracolumbar vertebral fractures in 425 Central Hospital of PLA from April 2010 to July 2015 were selected and divided into the primary osteoporotic thoracolumbar vertebral fractures(n=542) and hormone-induced osteoporotic thoracolumbar vertebral fractures(n=104) according to the fracture types.The incidence rate of refracture was compared between the two types of patients.The patients with hormone induced osteoporotic thoracolumbar fractures were divided into the fracture group and non-fracture group according to the refracture occurrence situation.The clinical data of the two groups were performed the univariate and multivariate Logistic regression analysis.Results There were 542 cases of primary osteoporosis,102 cases had refracture with the incidence rate of 18.82％,104 cases had hormone induced osteoporosis and 53 cases had refracture with the incidence rate of 50.96％.BMI,bone mineral density,bone cement leakage,preoperative vertebral fissure change and proportion of unreceiving anti-osteoporosis treatment had statistical difference between the fracture group and non-fracture group (P＜0.05).Bone mineral density,bone cement leakage,preoperative vertebral fissure change and no anti-osteoporosis treatment were the independent risk factors for refracture after PVP operation in the patients with steroid-induced thoracolumbar vertebral fracture (P＜0.05).Conclusion The patients with hormone induced osteoporotic thoracolumbar vertebral fracture have higher risk of refracture.Bone mineral density,bone cement leakage,preoperative vertebral fissure change,whether accepting anti-osteoporosis treatment are the major risk factors of refracture.
ABSTRACT
Objective: To investigate the pharmacological effects and mechanism of Leonuri Herba alkaloids (LHA) on prostate hyperplasia in older rats. Methods: The prostate hyperplasia model in older rats was induced by male and female hormone, the rats were divided into five groups: 50.0, 25.0, 12.5 mg/kg alkaloids dosage group, 30 mg/kg Longbishu Capsule suspension group, and model group given the same volume of saline. Otherwise aged rats and young rats were set as control groups administered with saline, and administered once daily for consecutive 30 d. The wet weight and prostate index in rat prostate were measured, and the expression of E2, DHT, T, bFGF, TGF-β1, EGF, and IGF-1 in serum and prostate tissue were detected after the experiment. The rat prostate tissue morphology changes and rat prostate cells ultrastructural changes were observed by light microscopy and transmission electron microscopy. Results: Compared with the model group, benign prostatic hyperplasia rat model was replicated successfully, low-dose LHA can significantly reduce the rat prostate wet weight and prostate index (P < 0.05), mid-dose LHA can significantly reduce the rat prostate index (P < 0.05). Each dose of LHA can significantly reduce the levels of T and DHT in prostate model rats (P < 0.01). Each dose of LHA can significantly reduce the expression of bFGF, EGF, and IGF-1 in prostate model rats (P < 0.01). Low-dose LHA can significantly increase the expression of TGF-β1 in prostate tissue. Each dose of LHA can significantly reduce the density of prostate model rats (P < 0.05, 0.01), and significantly increase the membrane surface and surface area values (P < 0.01). Each dose of LHA can significantly reduce intracytoplasmic mitochondria in prostate cells caused by model, and relieve the pathological changes of mitochondria cristae. Conclusion: LHA has good therapeutic effect to prostatic hyperplasia model rats induced by male and female hormone.